https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7973 Wed 11 Apr 2018 09:52:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34579 Wed 09 Mar 2022 16:00:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33818 Wed 04 Sep 2019 10:04:46 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14539 65 years) with ABD requiring parenteral sedation and physical restraint in the ED. Patients were treated with a standardized sedation protocol that included droperidol. Drug administration, time to sedation, additional sedation, and adverse effects were recorded. Effective sedation was defined as a drop in the sedation assessment tool score by 2 or a score of zero or less. Main Findings: There were 49 patients with median age of 81 years (range, 65-93 years); 33 were males. Thirty patients were given 10 mg droperidol, 15 were given 5 mg droperidol, 2 were given 2.5 mg, and 2 were given midazolam. Median time to sedation for patients receiving 10 mg droperidol was 30 minutes (interquartile range, 18-40 minutes), compared with 21 minutes (interquartile range, 10-55 minutes; P = .55) for patients receiving 5 mg droperidol. Three patients were not sedated within 120 minutes. Eighteen patients required additional sedation—10 of 30 (33%; 95% confidence interval, 18%-53%) given droperidol 10 mg compared with 7 of 15 (47%; 95% confidence interval, 22%-73%) given 5 mg. Fourteen patients required resedation. Adverse effects occurred in 5 patients (hypotension [2], oversedation [2], hypotension/oversedation [1])—2 of 30 given 10 mg droperidol and 3 of 19 not treated according to protocol. Midazolam was given initially or for additional sedation in 2 of 5 adverse effects. No patient had QT prolongation. Principal Conclusions: Droperidol was effective for sedation in most elderly patients with ABD, and adverse effects were uncommon. An initial 5-mg dose appears prudent with the expectation that many will require another dose.]]> Tue 31 Jul 2018 16:07:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34578 Tue 03 Sep 2019 18:22:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8428 Sat 24 Mar 2018 08:40:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13721 Sat 24 Mar 2018 08:22:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10611 Sat 24 Mar 2018 08:13:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18563 Sat 24 Mar 2018 07:50:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5441 Sat 24 Mar 2018 07:48:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25197 Sat 24 Mar 2018 07:14:01 AEDT ]]>